Cellectricon and Censo Biotechnologies collaborate

To offer high-quality Human iPSC-based discovery services for CNS and pain research

To offer high-quality Human iPSC-based discovery services for CNS and pain research

Cellectricon, provider of advanced cell-based discovery screening services, today announced a commercial collaboration with UK-based stem cell technology company Censo Biotechnologies. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research.

“Through our collaboration with Censo, we are able to significantly enhance our discovery services offering for CNS and pain research”, said Cellectricon’s CEO David Burns. “Censo’s extensive stem cell knowledge complements our current expertise and screening service offering in the field of neuroscience. This collaboration provides the opportunity to meet industry’s demands for drug discovery models that are closer, and therefore more relevant, to humans.

Aidan Courtney, CEO, Censo added, “Censo is committed to the use of ethically approved Human iPSCs and their derivatives to advance drug discovery. There is an excellent alignment between Censo and Cellectricon and we are excited about this collaboration. With our extensive expertise, we can provide important stem cell knowledge that adds further value to Cellectricon’s proprietary discovery services.”

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.